Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INV
4151
Innventure Inc
INV
$296M
| $249K | ﹤0.01% |
+59,464
| New | +$250K |
|
4152
SkinHealth Systems
SKIN
$84.2M
| $248K | ﹤0.01% |
178,287
+16,206
| +10% | +$23.4K |
|
|
CLYM
4153
Climb Bio
CLYM
$827M
| $247K | ﹤0.01% |
61,853
+37,100
| +150% | +$89.1K |
|
4154
DMC Global
BOOM
$155M
| $247K | ﹤0.01% |
36,964
+1,969
| +6% | +$13.6K |
|
4155
Mistras Group
MG
$556M
| $247K | ﹤0.01% |
19,548
-3,660
| -16% | -$41.3K |
|
4156
Hanover Bancorp
HNVR
$192M
| $247K | ﹤0.01% |
10,669
+1,769
| +20% | +$39.4K |
|
|
HDRNW
4157
Hadron Energy Warrant
HDRNW
$2.4M
| $246K | ﹤0.01% |
+600,000
| New | +$411K |
|
4158
Satellogic
SATL
$919M
| $245K | ﹤0.01% |
131,119
+33,882
| +35% | +$73.2K |
|
|
SNBR
4159
DELISTED
Sleep Number
SNBR
| $245K | ﹤0.01% |
28,959
-1,169
| -4% | -$7.39K |
|
4160
Dynagas LNG Partners
DLNG
$135M
| $244K | ﹤0.01% |
64,800
| – | – |
|
|
LPRO
4161
DELISTED
Open Lending Corp
LPRO
| $244K | ﹤0.01% |
157,383
+12,963
| +9% | +$23K |
|
|
NXDT
4162
NexPoint Diversified Real Estate Trust
NXDT
$250M
| $244K | ﹤0.01% |
63,639
+9,549
| +18% | +$31.3K |
|
4163
ProFrac Holding
ACDC
$936M
| $243K | ﹤0.01% |
62,516
+45,198
| +261% | +$185K |
|
4164
SKYX Platforms
SKYX
$163M
| $243K | ﹤0.01% |
111,909
+22,885
| +26% | +$40.8K |
|
4165
ROBO Global Robotics & Automation Index ETF
ROBO
$2.12B
| $243K | ﹤0.01% |
3,500
| – | – |
|
4166
Twin Disc
TWIN
$355M
| $241K | ﹤0.01% |
14,452
+12,227
| +550% | +$189K |
|
|
AMBQ
4167
Ambiq Micro
AMBQ
$1.58B
| $241K | ﹤0.01% |
8,451
+1,883
| +29% | +$53.9K |
|
4168
Landmark Bancorp
LARK
$197M
| $241K | ﹤0.01% |
9,196
+2,444
| +36% | +$64K |
|
|
XYZ
4169
CALL
Block Inc
XYZ
$47B
| $241K | ﹤0.01% |
3,700
-130,900
| -97% | -$9.03M |
|
4170
Under Armour Class C
UA
$2.2B
| $241K | ﹤0.01% |
50,120
-96,828
| -66% | -$431K |
|
4171
Vista Gold
VGZ
$339M
| $236K | ﹤0.01% |
+120,000
| New | +$231K |
|
4172
CALL
Aspen Aerogels
ASPN
$510M
| $236K | ﹤0.01% |
+83,400
| New | +$430K |
|
4173
China Yuchai International
CYD
$1.76B
| $236K | ﹤0.01% |
6,646
-13,873
| -68% | -$506K |
|
4174
Lifezone Metals
LZM
$352M
| $235K | ﹤0.01% |
55,097
+2,666
| +5% | +$12K |
|
|
VZLA
4175
Vizsla Silver
VZLA
$1.33B
| $235K | ﹤0.01% |
+42,934
| New | +$202K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.